The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC).
Matthew Raymond Smith
Consultant or Advisory Role - Astellas Pharma
Honoraria - Medivation
Michael Borre
No relevant relationships to disclose
Per Rathenborg
No relevant relationships to disclose
Patrick Werbrouck
No relevant relationships to disclose
Hendrik Van Poppel
No relevant relationships to disclose
Axel Heidenreich
Employment or Leadership Position - Astellas Pharma
Consultant or Advisory Role - Astellas Pharma
Honoraria - Astellas Pharma
Peter Iversen
Honoraria - Astellas Pharma
Edwina Baskin-Bey
Employment or Leadership Position - Astellas Pharma
Frank Perabo
Employment or Leadership Position - Astellas Pharma
De Phung
Employment or Leadership Position - Astellas Pharma
Bertrand Tombal
Consultant or Advisory Role - Astellas Pharma